JP7738482B2 - ピリダジノンｔｒｐｃ阻害剤の結晶形態 - Google Patents

ピリダジノンｔｒｐｃ阻害剤の結晶形態

Info

Publication number
JP7738482B2
JP7738482B2 JP2021555545A JP2021555545A JP7738482B2 JP 7738482 B2 JP7738482 B2 JP 7738482B2 JP 2021555545 A JP2021555545 A JP 2021555545A JP 2021555545 A JP2021555545 A JP 2021555545A JP 7738482 B2 JP7738482 B2 JP 7738482B2
Authority
JP
Japan
Prior art keywords
crystal
crystalline form
compound
pharmaceutical composition
ray diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021555545A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022525759A (ja
JP2022525759A5 (https=
Inventor
ガオ，ユエジュン
シュエ，ウェンフォン
Original Assignee
ジーエフビー（エービーシー）， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジーエフビー（エービーシー）， エルエルシー filed Critical ジーエフビー（エービーシー）， エルエルシー
Publication of JP2022525759A publication Critical patent/JP2022525759A/ja
Publication of JP2022525759A5 publication Critical patent/JP2022525759A5/ja
Priority to JP2025144862A priority Critical patent/JP2026004294A/ja
Application granted granted Critical
Publication of JP7738482B2 publication Critical patent/JP7738482B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
JP2021555545A 2019-04-10 2020-04-10 ピリダジノンｔｒｐｃ阻害剤の結晶形態 Active JP7738482B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025144862A JP2026004294A (ja) 2019-04-10 2025-09-01 ピリダジノンｔｒｐｃ阻害剤の結晶形態

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2019/081985 WO2020206623A1 (en) 2019-04-10 2019-04-10 Crystal forms
CNPCT/CN2019/081985 2019-04-10
PCT/US2020/027689 WO2020210639A1 (en) 2019-04-10 2020-04-10 Crystal forms of a pyridazinone trpc inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025144862A Division JP2026004294A (ja) 2019-04-10 2025-09-01 ピリダジノンｔｒｐｃ阻害剤の結晶形態

Publications (3)

Publication Number Publication Date
JP2022525759A JP2022525759A (ja) 2022-05-19
JP2022525759A5 JP2022525759A5 (https=) 2023-07-07
JP7738482B2 true JP7738482B2 (ja) 2025-09-12

Family

ID=70482847

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021555545A Active JP7738482B2 (ja) 2019-04-10 2020-04-10 ピリダジノンｔｒｐｃ阻害剤の結晶形態
JP2025144862A Pending JP2026004294A (ja) 2019-04-10 2025-09-01 ピリダジノンｔｒｐｃ阻害剤の結晶形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025144862A Pending JP2026004294A (ja) 2019-04-10 2025-09-01 ピリダジノンｔｒｐｃ阻害剤の結晶形態

Country Status (10)

Country Link
US (1) US20220177455A1 (https=)
EP (1) EP3953352A1 (https=)
JP (2) JP7738482B2 (https=)
CN (2) CN114502552B (https=)
AU (1) AU2026201003A1 (https=)
BR (1) BR112021018221A2 (https=)
CA (1) CA3136652A1 (https=)
MA (1) MA55614A (https=)
MX (2) MX2021012313A (https=)
WO (2) WO2020206623A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3684364A4 (en) 2017-09-18 2021-06-02 Goldfinch Bio, Inc. PYRIDAZINONE AND METHOD OF USE THEREOF
MA71645A (fr) * 2018-09-18 2025-05-30 Goldfinch Bio, Inc. Pyridazinones et leurs procédés d'utilisation
US12576033B2 (en) * 2019-04-11 2026-03-17 Gfb (Abc), Llc Spray-dried formulation of a pyridazinone TRPC5 inhibitor
JP2022551580A (ja) * 2019-10-04 2022-12-12 ゴールドフィンチ バイオ，インク． 巣状分節性糸球体硬化症および糖尿病性腎症のバイオマーカーに基づく処置
JP7539545B2 (ja) * 2020-07-03 2024-08-23 武漢朗来科技発展有限公司 複素環化合物及びその使用
US20250122190A1 (en) * 2021-09-10 2025-04-17 Medshine Discovery Inc. Halogen-substituted pyridazinone compound and application thereof
US20250082655A1 (en) * 2022-01-27 2025-03-13 Wuhan Createrna Science And Technology Co., Ltd. Use of heterocyclic compound
WO2024027752A1 (zh) * 2022-08-05 2024-02-08 武汉朗来科技发展有限公司 包含杂环化合物的药物组合物及其制备方法和应用
WO2025250920A1 (en) 2024-05-31 2025-12-04 Gfb (Abc), Llc Pyridazinone phosphate compounds, pharmaceutical compositions, and medical uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019055966A2 (en) 2017-09-18 2019-03-21 Goldfinch Bio, Inc. PYRIDAZINONES AND METHODS OF USE
WO2020061162A1 (en) 2018-09-18 2020-03-26 Goldfinch Bio, Inc. Pyridazinones and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP310798A0 (en) * 1998-04-22 1998-05-14 Soltec Research Pty Ltd Vehicle system for a composition comprising a piperidinopyrimidine derivative
US8633233B2 (en) * 2008-08-06 2014-01-21 Hydra Biosciences, Inc. Methods and compositions for treating anxiety
WO2016023830A1 (en) * 2014-08-11 2016-02-18 Hydra Biosciences, Inc. Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019055966A2 (en) 2017-09-18 2019-03-21 Goldfinch Bio, Inc. PYRIDAZINONES AND METHODS OF USE
WO2020061162A1 (en) 2018-09-18 2020-03-26 Goldfinch Bio, Inc. Pyridazinones and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
芦澤 一英、他，医薬品の多形現象と晶析の科学，丸善プラネット株式会社，2002年09月20日，第３０５－３１７頁

Also Published As

Publication number Publication date
AU2020272030B2 (en) 2025-11-13
AU2020272030A1 (en) 2021-11-11
MX2021012313A (es) 2021-11-17
CN114502552A (zh) 2022-05-13
AU2026201003A1 (en) 2026-03-05
MX2025006384A (es) 2025-07-01
JP2022525759A (ja) 2022-05-19
CN119264134A (zh) 2025-01-07
EP3953352A1 (en) 2022-02-16
MA55614A (fr) 2022-02-16
CN114502552B (zh) 2024-08-16
BR112021018221A2 (pt) 2022-01-18
US20220177455A1 (en) 2022-06-09
WO2020206623A1 (en) 2020-10-15
WO2020210639A1 (en) 2020-10-15
CA3136652A1 (en) 2020-10-15
JP2026004294A (ja) 2026-01-14

Similar Documents

Publication Publication Date Title
JP7738482B2 (ja) ピリダジノンｔｒｐｃ阻害剤の結晶形態
CN110151749B (zh) 冬凌草甲素在制备预防或治疗nlrp3炎症小体相关疾病的药物中的应用
EA028434B1 (ru) Лечение рака ингибиторами tor киназы
JP2025060685A (ja) ピリダジノンｔｒｐｃ５阻害剤の噴霧乾燥された製剤
JP2025183335A (ja) 巣状分節性糸球体硬化症および糖尿病性腎症のバイオマーカーに基づく処置
AU2025205402A1 (en) New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases
JP2930281B2 (ja) 皮膚疾患処置用薬剤
JP2004534760A (ja) 腎線維症の治療
AU2020272030C1 (en) Crystal forms of a pyridazinone TRPC inhibitor
HK40122791A (zh) 哒嗪酮trpc抑制剂的晶体形式
BR122025019562A2 (pt) Formas cristalinas de um inibidor de trpc de piridazinona, composição farmacêutica que as compreende e uso das mesmas
KR102956339B1 (ko) 피리다진온 trpc5 억제제의 분무 건조된 제형
BR122025019564A2 (pt) Dispersão seca por pulverização, composição para sua formulação e método de fabricação da mesma, forma de dosagem sólida e seu método de fabricação, e uso de um inibidor de piridazinona trpc5 para tratar dor, ansiedade ou depressão
WO2026067059A1 (zh) Jak2抑制剂在制备治疗慢性肾脏病的药物中的用途
WO2026002229A1 (zh) 一种nlrp3抑制剂化合物及其制备方法和应用
KR20260059680A (ko) 피리다진온 trpc5 억제제의 분무 건조된 제형
JP2024538054A (ja) 高シュウ酸尿症及び腎結石の治療のための１ｈ－１，２，３－トリアゾール－４－カルボン酸
CN118043050A (zh) 用固体形式的比托哌汀治疗红细胞生成性原卟啉病、x连锁原卟啉病或先天性红细胞生成性卟啉病的方法
TW200522962A (en) Neutrophilia inhibitor
OA19594A (en) Use of a glutarimide derivative to treat diseases related to the aberrant activity of cytokines
EA043907B1 (ru) Применение производного глутаримида для лечения заболеваний, связанных с аберрантной активностью цитокинов
JP2003238408A (ja) 組織線維症の治療剤または予防剤
SI9400099A (sl) Lizinova sol 6-kloro-5-fluoro-3-{2-tenoil)-2-oksindol-1-karboksiamida

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220228

RD12 Notification of acceptance of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7432

Effective date: 20221216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230407

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230622

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240507

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240806

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241031

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250205

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20250228

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20250305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250305

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250331

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250707

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250804

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250902

R150 Certificate of patent or registration of utility model

Ref document number: 7738482

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150